Artiva Biotherapeutics, Inc. Operating Income Loss

Quick Answer

Artiva Biotherapeutics, Inc. reported Operating Income Loss of -$89.81 million for the year ending 2025.

  • Artiva Biotherapeutics, Inc. showed a decrease of -33.5% in Operating Income Loss from 2024 to 2025.
  • This data is from Artiva Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Artiva Biotherapeutics, Inc.'s Operating Income Loss has declined by 192.8%.
  • Historical annual values: Fiscal year 2025: -$89.81 million | Fiscal year 2024: -$67.28 million | Fiscal year 2023: -$30.67 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: